/ Print /

IN THE PIPELINE

Generic versions of major depression drug availableMylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
CVS Health Names New COO
CVS Health Names New COOJonathan C. Roberts is named Executive Vice President and COO.
Reactions to the Proposed American Health Care Act
Reactions to the Proposed American Health Care ActAnalysts and columnists from the left and right have had time to react to the new healthcare replacement plan. What are they saying?
Meijer’s Expansion Includes Pharmacy Upgrades
Meijer’s Expansion Includes Pharmacy UpgradesMeijer will improve and expand pharmacies across its new and remodeled stores.
New Insights on Treatment Refusal of Pharmacotherapy and Psychotherapy
New Insights on Treatment Refusal of Pharmacotherapy and PsychotherapyA meta-analysis casts light on therapy compliance issues among patients with different mental health disorders.
Once-daily diabetes drug approvedFDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes.
Drug approved for nighttime urination, plus two moreFDA recently approved three novel drugs: one to treat frequent urination at night, one to treat carcinoid syndrome diarrhea in cancer patients, and one for dust mite allergies. Here are the details on the three new treatments.
Tests help aid in antibiotic controlFDA recently approved 2 tests that will aid healthcare providers in determining which antibiotics are needed, leading to better antibiotics management.
HIV dual therapy shows promiseA dual-drug regiment to treat HIV could soon be a reality, according to results presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Psoriasis drug approved with boxed warningA new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.